Fidelity SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

Catasys Inc. (CATS)

CATS RSS Feed
Add CATS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator
Search This Board:
Last Post: 7/1/2014 11:06:51 AM - Followers: 15 - Board type: Free - Posts Today: 0

 

Company Overview:

Hythiam, Inc. provides through its Catasys® subsidiary, specialized behavioral health management services to health plans, employers and unions through a network of licensed and company managed health care providers. The Catasys Substance Dependence Program was designed to address substance dependence as a chronic disease. The program seeks to lower costs and improve member health through the delivery of integrated medical and psychosocial interventions in combination with long term care coaching, including the proprietary Prometa® Treatment Program for alcoholism and stimulant dependence. The Prometa Treatment Program, which integrates behavioral, nutritional, and medical components, is also available on a private-pay basis through licensed treatment providers.

Hythiam Inc. Corporate Presentation 2010

Contact Info

  • 11150 Santa Monica Boulevard
  • Los Angeles, CA
  • United States, 90025

Providing specialized behavioral health management services to health plans, employers and unions through a network of licensed and company managed health care providers.

For more info CatasysHealth.com

 

If you or someone you know has been struggling with substance dependence, it is important to recognize that it involves much more than just behavior. The reality is, physical, psychological, and social factors all contribute to the disease.
 
For more information on Prometa, visit prometainfo.com
 
 
 

Hythiam Leadership Team

 

Terren S. Peizer
Chairman and Chief Executive Officer

 
   

Terren S. Peizer is the founder of our company and has served as our chief executive officer and chairman of our Board of Directors since our inception in February 2003. He has served as Managing Director of Socius Capital Partners, LLC, since September 2009. Mr. Peizer has served on the board of Xcorporeal, Inc. since August 2007 and was executive chairman until October 2008. Mr. Peizer also served as chief executive officer of Clearant, Inc., a company which he founded in April 1999 to develop and commercialize a universal pathogen inactivation technology, until October 2003. He served as chairman of its board of directors from April 1999 to October 2004 and as a director until February 2005. In addition, from June 1999 through May 2003 he was a director, and from June 1999 through December 2000 he was chairman of the board, of supercomputer designer and builder Cray Inc., a NASDAQ Global Market company. Mr. Peizer has been the largest beneficial stockholder and has held various senior executive positions with several technology and biotech companies. He has assisted companies by assembling management teams, boards of directors and scientific advisory boards, formulating business and financial strategies, and investor relations. Mr. Peizer has a background in venture capital, investing, mergers and acquisitions, corporate finance, and previously held senior executive positions with the investment banking firms Goldman Sachs, First Boston and Drexel Burnham Lambert. He received his B.S.E. in Finance from The Wharton School of Finance and Commerce.

 

Rick A. Anderson
President and Chief Operating Officer

 
   

Richard A. Anderson has more than fifteen years of experience in business development, strategic planning and financial management. He has served as a director since July 2003 and an officer since April 2005. He was the chief financial officer of Clearant, Inc. from November 1999 until March 2005, and served as a director from November 1999 to March 2006.  Mr. Anderson was previously a director and founding member of PriceWaterhouseCoopers LLP’s, Los Angeles office transaction support group, where he was involved in operational and financial due diligence, valuations and structuring for high technology companies. He received a B.A. in Business Economics from University of California, Santa Barbara.

 

Peter Donato
Chief Financial Officer

 
   

Peter Donato has nearly 20 years of progressive financial management experience in large, publicly traded companies as well as small, entrepreneurial companies. He began his career in public accounting with Ernst & Young, and most recently served as CFO of Iris International, a NASDAQ traded medical diagnostics equipment manufacturer, and CFO of Gamma Medica-Ideas, an early stage medical imaging company.  He is credited for establishing a strong and timely reporting structure, improved control environment, recruiting and retaining strong accounting, finance and IT teams, as well as developing and maintaining strong relationships with external stakeholders including: investors, coverage analysts, bankers, insurance brokers and auditors.  He has held positions with increasing responsibilities at General Motors, Honda, Scotts-Miracle Gro, and Accellent.  Mr. Donato graduated from The Ohio State University with a BS in Business Administration and earned an MBA from the University of Akron.

 

Gary Ingenito, MD, PhD
SVP of Scientific Affairs

 
   

Dr. Ingenito is responsible for preclinical and clinical scientific research and development. He is a member of the senior executive management team, providing strategic direction for future clinical trials, clinical product development, creation of expanded patient treatment algorithms, data analysis and reporting. Dr. Ingenito previously held executive positions at Angiotech, SFBC International, Otsuka Pharmaceuticals, Corning-Besselaar, and Novartis. A neurologist, Dr. Ingenito
received his bachelor’s degree from Johns Hopkins University, an MD from Jefferson Medical College and a PhD in microbiology/cellular immunology from Thomas
Jefferson University.

 



W. Gregory McLane
SVP Sales and Marketing

 
   

Mr. McLane is responsible for the overall sales and marketing efforts of the company, encompassing customer acquisition, marketing strategy, market research, member outreach and account management. Prior to joining the company he led the marketing activities for Magellan Health Services and founded Optimized Benefits, Inc., a health benefits company that replaced the one-size-fits-all HMO, PPO and CDHP plans with “Life Stage” plans which address the different needs of employees at various stages of their lives. He also led strategy development and product development for CIGNA and ran consumer products businesses for Procter & Gamble, Campbell Soup and Nabisco. Mr. McLane earned a Bachelor of Science degree from The Wharton School of the University of Pennsylvania with majors in accounting and decision science, and a Masters of Business Administration from Cornell University with concentrations in management and organizational behavior.

 



Lawrence M. Weinstein, MD
SVP of Medical Affairs

 
   

Dr. Weinstein leads the clinical initiatives for the development of clinical products and provides medical leadership for the business development, marketing and site management departments. Dr. Weinstein also serves as the primary clinical liaison to licensees, physician groups, corporate affiliations, managed care organizations, insurers and external affairs. Prior to Catasys, Dr. Weinstein held positions at PacifiCare Behavioral Health/United Behavioral Health, Magellan Behavioral Health and the Chemical Dependence Unit at St. Elizabeth’s Hospital in Chicago. He has also worked in private practice providing individual and group diagnostic and psychotherapeutic services, as well as family therapy. Dr. Weinstein received his M.D. from the Ross University School of Medicine, and completed his internship and residency in psychiatry at Michael Reese Hospital and Medical Center in Chicago.

 

Hythiam Board of Directors

 
Terren S. Peizer
Chairman and Chief Executive Officer

Terren S. Peizer is the founder of our company and has served as our chief executive officer and chairman of our Board of Directors since our inception in February 2003. He has served as Managing Director of Socius Capital Partners, LLC, since September 2009. Mr. Peizer has served on the board of Xcorporeal, Inc. since August 2007 and was executive chairman until October 2008. Mr. Peizer also served as chief executive officer of Clearant, Inc., a company which he founded in April 1999 to develop and commercialize a universal pathogen inactivation technology, until October 2003. He served as chairman of its board of directors from April 1999 to October 2004 and as a director until February 2005. In addition, from June 1999 through May 2003 he was a director, and from June 1999 through December 2000 he was chairman of the board, of supercomputer designer and builder Cray Inc., a NASDAQ Global Market company. Mr. Peizer has been the largest beneficial stockholder and has held various senior executive positions with several technology and biotech companies. He has assisted companies by assembling management teams, boards of directors and scientific advisory boards, formulating business and financial strategies, and investor relations. Mr. Peizer has a background in venture capital, investing, mergers and acquisitions, corporate finance, and previously held senior executive positions with the investment banking firms Goldman Sachs, First Boston and Drexel Burnham Lambert. He received his B.S.E. in Finance from The Wharton School of Finance and Commerce.

Rick A. Anderson
President and Chief Operating Officer

Rick A. Anderson, has more than fifteen years of experience in business development, strategic planning and financial management. He has served as a director since July 2003 and an officer since April 2005. He was the chief financial officer of Clearant, Inc. from November 1999 until March 2005, and served as a director from November 1999 to March 2006.  Mr. Anderson was previously a director and founding member of PriceWaterhouseCoopers LLP’s, Los Angeles office transaction support group, where he was involved in operational and financial due diligence, valuations and structuring for high technology companies. He received a B.A. in Business Economics from University of California, Santa Barbara.
 


Andrea Grubb Barthwell, M.D., F.A.S.A.M.

Andrea Grubb Barthwell, M.D., F.A.S.A.M., is the founder and Chief Executive Officer of the global health care and policy-consulting firm EMGlobal LLC and Director at Two Dreams Outer Banks Treatment Center.  President George W. Bush nominated Dr. Barthwell in December 2001 to serve as Deputy Director for Demand Reduction in the Office of National Drug Control Policy (ONDCP).  The United States Senate confirmed her nomination on January 28, 2002.  As a member of the President's sub-cabinet, Dr. Barthwell was a principal advisor in the Executive Office of the President (EOP) on policies aimed at reducing the demand for illicit drugs. Dr. Barthwell received a Bachelor of Arts degree in Psychology from Wesleyan University, where she serves on the Board of Trustees, and a Doctor of Medicine from the University of Michigan Medical School.  Following post-graduate training at the University of Chicago and Northwestern University Medical Center, she began her practice in the Chicago area.  Dr. Barthwell served as President of the Encounter Medical Group (EMG, an affiliate of EMGlobal), was a founding member of the Chicago Area AIDS Task Force, hosted a weekly local cable show on AIDS, and is a past president of the American Society of Addiction Medicine.  Dr. Barthwell received the Betty Ford Award, given by the Association for Medical Education and Research in Substance Abuse and has been named by her peers as one of the "Best Doctors in America" in addiction medicine.

Marc G. Cummins

Marc G. Cummins is a managing partner of Prime Capital, LLC, a private investment firm focused on consumer companies.  Prior to founding Prime Capital, Mr. Cummins was managing partner of Catterton Partners, a private equity investor in consumer products and service companies with more than $1 billion of assets under  management. Prior to joining Catterton in 1998, Mr. Cummins spent fourteen years at Donaldson, Lufkin & Jenrette Securities Corporation where he was managing director of the Consumer Products and Specialty Distribution Group, and was also involved in leveraged buyouts, private equity and high yield financings.  Mr. Cummins received a B.A. in Economics, magna cum laude, from Middlebury College, where he was honored as a Middlebury College Scholar and is a member of Phi Beta Kappa. He also received an M.B.A. in Finance with honors from The Wharton School at University of Pennsylvania.

Jay A. Wolf

Jay A. Wolf has served as a director since June 2008.  He is the founder and principal of Wolf Capital LP an investment advisory firm he formed in October 2009 to focus on small cap public companies. From November 2003 until September 2009, Mr. Wolf was a partner at Trinad Capital LLC, an activist hedge fund focused on micro-cap public companies. During his work at Trinad, Mr. Wolf assisted distressed and early stage public companies through active board participation, the assembly of management teams and business and financial strategies. Prior to his work at Trinad, Mr. Wolf served as executive vice president of Corporate Development for Wolf Group Integrated Communications Ltd. Prior to that, Mr. Wolf worked at Canadian Corporate Funding, Ltd., a Toronto-based merchant bank as an analyst in the firm’s senior debt department and subsequently for Trillium Growth Capital, the firm’s venture capital fund. Mr. Wolf currently also sits on the boards of Xcorporeal, Inc. (XCR), Zoo Entertainment, Inc. (ZOOE) and NorthStar Systems, Inc. Mr. Wolf is also a member of the board of governors at Cedars-Sinai Hospital. He is a former director of Asianada, Inc., ProLink Holdings Corp., Mandalay Media, Inc., Atrinsic, Inc., Shells Seafood Restaurants, Inc., Optio Software, Inc., Xcorporeal Operations, Inc., Zane Acquisition I, Inc., Zane Acquisition II, Inc., Starvox Communications, Inc. and Noble Medical Technologies, Inc. Mr. Wolf received his B.A from Dalhousie University.  Mr. Wolf was chief operating officer and chief financial officer of Starvox Communications, Inc. from March 2005 to March 2007.  On March 26, 2008, StarVox Communications, Inc. filed a voluntary petition for liquidation under Chapter 7 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Northern District of California, San Jose. Shells Seafood Restaurants, Inc., a company for which Mr. Wolf formerly served as a director, filed a voluntary petition for reorganization under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Middle District of Florida, Tampa Division, on September 2, 2008.  Mr. Wolf’s broad range of investment and operations experience, which includes senior and subordinated debt lending, private equity and venture capital investments, mergers and acquisitions advisory work and public equity investments, equip him with the qualifications and skills to serve on our Board of Directors.
 

 

SEC Filings

Form Type Received Period Ending Size Report
POS AM Oct 1, 2010   49.2 KB PDF    RTF    HTML    XLS
POS AM Oct 1, 2010   48.5 KB PDF    RTF    HTML    XLS
AW Sept 28, 2010   12.6 KB PDF    RTF    HTML   
AW Sept 28, 2010   12.6 KB PDF    RTF    HTML   
POS EX Sept 21, 2010   48.6 KB PDF    RTF    HTML    XLS
POS EX Sept 21, 2010   49.4 KB PDF    RTF    HTML    XLS
3 Sept 3, 2010 Aug 25, 2010 4.3 KB PDF    RTF    HTML    XLS
8-K Aug 27, 2010 Aug 25, 2010 38.5 KB PDF    RTF    HTML    XLS
10-Q Aug 16, 2010 Jun 30, 2010 1.2 MB PDF    RTF    HTML    XLS
8-K Jul 7, 2010 Jul 7, 2010 18.8 KB PDF    RTF    HTML    XLS



 
 
Shares Outstanding 55,154,688 a/o Apr 28, 2009

Transfer Agent(s)

American Stock Transfer & Trust Company
 
 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CATS
Current Price
Volume:
Bid Ask Day's Range
Wiki
PostSubject
#354   Catasys Inc. [$CATS] due diligence stocktrademan 07/01/14 11:06:51 AM
#353   just put on my list 2 days ago. dshade 06/21/14 12:18:30 PM
#352   Is it finally time for this CAT to markymark12 06/11/14 04:56:44 PM
#351   Crede Capital and Terren Peizer continue to invest markymark12 06/11/14 04:56:33 PM
#350   Don't be surprise if you see double digit Anwarpatel 06/06/14 02:25:17 PM
#349   Double split, insider buying...what's the deal with this company? Raphael De La Ghetto 04/21/14 06:27:22 PM
#348   CATS one for 10 reverse split: Renee 05/06/13 05:16:24 PM
#347   CATS .115 178k vs 1.4k_vol10dayavg 10day alert, low float Klait 04/23/13 10:36:13 PM
#346   setting up Roy London 04/23/13 07:22:07 PM
#345   patience Roy London 01/31/13 01:36:03 PM
#344   Nice hit ~50k Sentrex1969 01/31/13 01:02:24 PM
#343   looking for .19 .20 Roy London 12/08/12 01:28:31 PM
#342   oversold Roy London 12/04/12 01:56:23 PM
#341   Reg SHO Threshold List: CATS srm4u 11/04/12 07:48:04 PM
#340   SS Roy London 11/04/12 01:10:08 PM
#339   insider buys Roy London 11/04/12 01:08:13 PM
#338   ..WATCH!!!! Explosive chart forming..and this one has the Roy London 11/04/12 01:05:24 PM
#337   Catasys Commences Enrollment With Coventry Health Care of Oklahoma juggernutt 05/15/12 12:21:37 PM
#336   May 11 http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8611553 Alice-N-Wonderland 05/14/12 01:29:41 AM
#335   Heard that this Co is expecting explosive growth. juggernutt 05/10/12 01:14:12 PM
#334   new to this stock...anything good about it? IPO$ 12/12/11 01:04:35 PM
#333   CATASYS news Jukimol 09/30/11 04:37:47 AM
#332   CATS: One for 40 R/S. Bad kitty!!! Renee 09/02/11 05:17:43 PM
#331   Catasys Launches Its Integrated Substance Dependence Program in 417steve 06/16/11 10:13:16 AM
#330   what do you use for the chart? i Hedge Starz 06/06/11 09:10:02 PM
#329   hmmm i like that share structure and the Caerus 06/06/11 09:08:29 PM
#328   gotta feelin a r/s is in the air. Caerus 06/06/11 09:02:56 PM
#327   that is a MONSTER OS Hedge Starz 06/06/11 08:59:24 PM
#326   Shares Oustanding: 834.4 mill Caerus 05/18/11 03:15:52 PM
#325   Peizer is quoted in saying "nobody cares about Superfly15 04/27/11 01:45:54 AM
#324   Just waiting and hoping. No big position here. 417steve 03/23/11 05:39:43 PM
#323   No reply needed, just read some of the MR 1955 DOUBLE DIE 03/22/11 10:09:34 PM
#322   Just saw the story myself. Treatment seems to work... MR 1955 DOUBLE DIE 03/22/11 09:43:49 PM
#321   CNBC Tue, Mar 22 Kelroz 03/22/11 09:36:39 PM
#320   Matt from admin said it would be fixed 417steve 03/21/11 06:04:29 PM
#319   You are correct sir! They had it correct 417steve 03/21/11 03:49:03 PM
#318   something is not right with the ihub quote dealerschool2006 03/21/11 01:20:51 PM
#317   NEWS: Hythiam to Present at the Roth 23rd 417steve 03/08/11 10:08:35 AM
#316   NEWS: Hythiam, Inc Announces Results of Special Meeting 417steve 03/07/11 10:03:30 AM
#315   HYTM ..Hythiam to become Massive P&D Admiral Lagrange 02/22/11 06:29:46 PM
#314   NEWS: Hythiam Announces Catasys Contract with Coventry Health 417steve 01/05/11 10:50:32 AM
#313   I got my alerts set Hacktheripper 12/20/10 03:04:28 PM
#312   Ever since it hit the bottom of .02 417steve 12/20/10 02:48:51 PM
#311   Nice movement .09 1.2M traded Hacktheripper 12/20/10 01:07:55 PM
#310   Ya, somewhere along the way IHUB lost track 417steve 11/29/10 08:12:40 PM
#309   Yes, I figured as much. ( : slojab 11/29/10 08:02:46 PM
#308   Hey Slojab. How ya doing? The "Yay" was 417steve 11/29/10 07:54:03 PM
#307   Yay? Are you sure you didn't mean YIKES! slojab 11/29/10 07:49:37 PM
#306   hey steve sorry my ranting earlier wasn't personal.. TeeHeeHee 11/17/10 05:45:00 PM
#305   Wow! You're harsh for someone that doesn't even 417steve 11/17/10 05:09:04 PM
PostSubject